CA2730665C - Forme galenique contenant une statine - Google Patents

Forme galenique contenant une statine Download PDF

Info

Publication number
CA2730665C
CA2730665C CA2730665A CA2730665A CA2730665C CA 2730665 C CA2730665 C CA 2730665C CA 2730665 A CA2730665 A CA 2730665A CA 2730665 A CA2730665 A CA 2730665A CA 2730665 C CA2730665 C CA 2730665C
Authority
CA
Canada
Prior art keywords
dosage form
pharmaceutically acceptable
stable
rosuvastatin
form according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2730665A
Other languages
English (en)
Other versions
CA2730665A1 (fr
Inventor
Mathew Philip
Naresh Talwar
Shruti Bhat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmascience Inc
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Priority to CA2730665A priority Critical patent/CA2730665C/fr
Publication of CA2730665A1 publication Critical patent/CA2730665A1/fr
Application granted granted Critical
Publication of CA2730665C publication Critical patent/CA2730665C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une nouvelle forme galénique pharmaceutique stable qui contient une statine et des procédés pour préparer de telles formes galéniques, la forme galénique étant pratiquement exempte d'agents de stabilisation et la statine étant combinée aux excipients de qualité pharmaceutique suivants : du dioxyde de silicium colloïdal, de la cellulose microcristalline et du monohydrate de lactose.
CA2730665A 2008-07-15 2009-07-14 Forme galenique contenant une statine Expired - Fee Related CA2730665C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2730665A CA2730665C (fr) 2008-07-15 2009-07-14 Forme galenique contenant une statine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA002637977A CA2637977A1 (fr) 2008-07-15 2008-07-15 Forme pharmaceutique contenant une statine
CA2,637,977 2008-07-15
CA2730665A CA2730665C (fr) 2008-07-15 2009-07-14 Forme galenique contenant une statine
PCT/CA2009/001031 WO2010006451A1 (fr) 2008-07-15 2009-07-14 Forme galénique contenant une statine

Publications (2)

Publication Number Publication Date
CA2730665A1 CA2730665A1 (fr) 2010-01-21
CA2730665C true CA2730665C (fr) 2017-01-03

Family

ID=41549981

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002637977A Abandoned CA2637977A1 (fr) 2008-07-15 2008-07-15 Forme pharmaceutique contenant une statine
CA2730665A Expired - Fee Related CA2730665C (fr) 2008-07-15 2009-07-14 Forme galenique contenant une statine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002637977A Abandoned CA2637977A1 (fr) 2008-07-15 2008-07-15 Forme pharmaceutique contenant une statine

Country Status (2)

Country Link
CA (2) CA2637977A1 (fr)
WO (1) WO2010006451A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200904341A2 (tr) * 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
WO2013083674A1 (fr) * 2011-12-08 2013-06-13 Hexal Ag Nouvelle composition pharmaceutique à base de statine
CN105796518B (zh) * 2016-04-08 2018-06-12 山东省中医药研究院 一种黄独素b分散片及其制备方法
CN113143882A (zh) * 2021-04-30 2021-07-23 海南通用三洋药业有限公司 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
WO2006054308A2 (fr) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Formulations d'atorvastatine stables
EP1923057A1 (fr) * 2005-11-21 2008-05-21 Teva Pharmaceutical Industries Ltd Formule pharmaceutique atorvastanine

Also Published As

Publication number Publication date
CA2730665A1 (fr) 2010-01-21
WO2010006451A1 (fr) 2010-01-21
CA2637977A1 (fr) 2010-01-15

Similar Documents

Publication Publication Date Title
WO2009024889A2 (fr) Composition pharmaceutique comprenant un inhibiteur de réductase hmg-coa et un ézétimibe
US20070202159A1 (en) Pharmaceutical composition comprising stabilized statin particles
CN103800279B (zh) 阿托伐他汀钙组合物
MX2014013241A (es) Formulacion de tableta oral que consiste de una combinacion fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares.
EP2448919A2 (fr) Formulation pharmaceutique permettant d'augmenter la solubilité et la stabilité
JP5722034B2 (ja) １種または複数のＨＭＧ−ＣｏＡレダクターゼ阻害剤を含む安定的な医薬組成物
CN101972260B (zh) 一种瑞舒伐他汀钙口服药物组合物
CA2730665C (fr) Forme galenique contenant une statine
WO2011139256A2 (fr) Formulations stables de rosuvastatine
EP2233133B1 (fr) Compositions stables comprenant de Rosuvastatine
US20120027854A1 (en) Pharmaceutical composition comprising ezetimibe and simvastatin
EP2328563A1 (fr) Préparation pharmaceutique améliorant la solubilité
US20150037414A1 (en) Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin
EP1651194B1 (fr) Compositions pharmaceutiques stables a liberation controlee contenant du fenofibrate et de la pravastatine
EP1968593B1 (fr) Composition pharmaceutique comprenant de l'acide (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoique
EP3833335A1 (fr) Composition pharmaceutique comprenant des inhibiteurs de la hmg-coa réductase et du fénofibrate
KR101302306B1 (ko) 고지혈증 복합제
WO2009091346A2 (fr) Formulation pharmaceutique stable et procédés de préparation
EP4566591A1 (fr) Forme pharmaceutique solide comprenant de l'ézétimibe et de la pitavastatine
WO2013072770A2 (fr) Formulations pharmaceutiques comprenant de l'atorvastatine et du glimépiride
US20100178338A1 (en) Stabilized pharmaceutical compositions comprising atorvastatin
KR20100063672A (ko) 에이취엠지-코에이 환원효소 억제제를 함유하는 안정한 약제학적 조성물
PL218999B1 (pl) Kompozycja farmaceutyczna zawierająca rosuwastatynę, sposób jej wytwarzania oraz stała postać leku zawierająca tę kompozycję
HK1216079B (en) Complex formulation containing sustained release metformin and immediate release hmg-coa reductase inhibitor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140617

MKLA Lapsed

Effective date: 20200831